NTRB
Price
$5.56
Change
-$0.08 (-1.42%)
Updated
Nov 14, 01:07 PM (EDT)
Capitalization
67.65M
17 days until earnings call
Intraday BUY SELL Signals
RGNX
Price
$11.75
Change
+$0.11 (+0.95%)
Updated
Nov 14, 02:47 PM (EDT)
Capitalization
589.25M
109 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NTRB vs RGNX

Header iconNTRB vs RGNX Comparison
Open Charts NTRB vs RGNXBanner chart's image
Nutriband
Price$5.56
Change-$0.08 (-1.42%)
Volume$1.2K
Capitalization67.65M
REGENXBIO
Price$11.75
Change+$0.11 (+0.95%)
Volume$300
Capitalization589.25M
NTRB vs RGNX Comparison Chart in %
NTRB
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NTRB vs. RGNX commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRB is a Hold and RGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (NTRB: $5.64 vs. RGNX: $11.64)
Brand notoriety: NTRB and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTRB: 51% vs. RGNX: 100%
Market capitalization -- NTRB: $67.65M vs. RGNX: $589.25M
NTRB [@Biotechnology] is valued at $67.65M. RGNX’s [@Biotechnology] market capitalization is $589.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTRB’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • NTRB’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than NTRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTRB’s TA Score shows that 3 TA indicator(s) are bullish while RGNX’s TA Score has 3 bullish TA indicator(s).

  • NTRB’s TA Score: 3 bullish, 6 bearish.
  • RGNX’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than NTRB.

Price Growth

NTRB (@Biotechnology) experienced а +1.99% price change this week, while RGNX (@Biotechnology) price change was +4.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.64%. For the same industry, the average monthly price growth was -3.56%, and the average quarterly price growth was +66.73%.

Reported Earning Dates

NTRB is expected to report earnings on Dec 01, 2025.

RGNX is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+3.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($589M) has a higher market cap than NTRB($67.6M). RGNX YTD gains are higher at: 50.582 vs. NTRB (19.745). NTRB has higher annual earnings (EBITDA): -9.99M vs. RGNX (-129.93M). RGNX has more cash in the bank: 323M vs. NTRB (7M). NTRB has less debt than RGNX: NTRB (270K) vs RGNX (77.7M). RGNX has higher revenues than NTRB: RGNX (156M) vs NTRB (2.58M).
NTRBRGNXNTRB / RGNX
Capitalization67.6M589M11%
EBITDA-9.99M-129.93M8%
Gain YTD19.74550.58239%
P/E RatioN/AN/A-
Revenue2.58M156M2%
Total Cash7M323M2%
Total Debt270K77.7M0%
FUNDAMENTALS RATINGS
NTRB vs RGNX: Fundamental Ratings
NTRB
RGNX
OUTLOOK RATING
1..100
8375
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6344
P/E GROWTH RATING
1..100
10017
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTRB's Valuation (48) in the null industry is in the same range as RGNX (73) in the Biotechnology industry. This means that NTRB’s stock grew similarly to RGNX’s over the last 12 months.

NTRB's Profit vs Risk Rating (100) in the null industry is in the same range as RGNX (100) in the Biotechnology industry. This means that NTRB’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's SMR Rating (97) in the Biotechnology industry is in the same range as NTRB (100) in the null industry. This means that RGNX’s stock grew similarly to NTRB’s over the last 12 months.

RGNX's Price Growth Rating (44) in the Biotechnology industry is in the same range as NTRB (63) in the null industry. This means that RGNX’s stock grew similarly to NTRB’s over the last 12 months.

RGNX's P/E Growth Rating (17) in the Biotechnology industry is significantly better than the same rating for NTRB (100) in the null industry. This means that RGNX’s stock grew significantly faster than NTRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTRBRGNX
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 11 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
66%
View a ticker or compare two or three
Interact to see
Advertisement
NTRB
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LVAFX12.02-0.01
-0.08%
LSV Global Managed Volatility Investor
GABUX5.07-0.04
-0.78%
Gabelli Utilities AAA
RMGSX11.96-0.10
-0.83%
Russell Inv Multi-Asset Strat S
JOPPX52.54-0.46
-0.87%
Johnson Opportunity
TRLWX25.19-0.33
-1.29%
Nuveen Large Cap Value W

NTRB and

Correlation & Price change

A.I.dvisor tells us that NTRB and ABSI have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTRB and ABSI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTRB
1D Price
Change %
NTRB100%
-3.75%
ABSI - NTRB
31%
Poorly correlated
-22.35%
VRAX - NTRB
31%
Poorly correlated
+5.14%
SONN - NTRB
29%
Poorly correlated
+13.45%
DNLI - NTRB
29%
Poorly correlated
-2.11%
RGNX - NTRB
29%
Poorly correlated
+0.34%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+0.34%
SYRE - RGNX
57%
Loosely correlated
-3.41%
DNLI - RGNX
55%
Loosely correlated
-2.11%
BEAM - RGNX
54%
Loosely correlated
-0.96%
VYGR - RGNX
54%
Loosely correlated
-6.35%
RXRX - RGNX
54%
Loosely correlated
-6.88%
More